The Volpara Health Technologies Ltd (ASX: VHT) share price is climbing today following the release of the company's quarterly report.
At the time of writing, the healthcare technology company's shares are up 1.17% to $1.295.
How did Volpara perform for Q2 FY22?
According to its release, Volpara advised record sales and cash inflows for the 3 months ending 30 September.
In particular, cash receipts from customers totalled NZ$7.1 million (A$6.79 million), an increase of 11% on the previous quarter. Compared against the prior corresponding period, this metric grew 52% — or 68% in constant currency terms.
Subscription-based receipts continued to accelerate, representing more than NZ$6.9 million (A$6.60 million) for the 3 months. This is a jump of 63% year-on-year, or roughly 74% in constant currency.
Net operating cash outflow came to NZ$3.8 million (A$3.63 million), consistent with Q2 FY21. Some material supplier contract renewals, such as its annual insurance program, kept the costs in line.
Volpara noted that it closed the quarter with cash of NZ$25 million (AS23.91) on hand and no debt.
On the Software-as-a-Service (SaaS) front, annual recurring revenue (ARR) stood at US$20.4 million (A$27.24) million. Contracts were signed across the company's full product suite as both standalone sales and platform deals. Many existing customers also increased contracts with Volpara whether by adding on products or expanding use of existing products.
The average revenue per user (ARPU) improved to US$1.46 (A$1.95), up 5% on the prior quarter. Its legacy MRS support contracts were heavily weighted towards the lower ARPU ranges, while its subscription-based products weighted more to the higher ARPUs.
Volpara group CEO Dr Ralph Highnam commented:
Q2 is traditionally our weakest quarter for sales, and yet today we've shown that we've had a record quarter not only for sales but also cash inflows.
…Our job now is to keep that momentum and passion for what we do as we go through the second half of the year, keeping in mind potential winter waves of COVID in the northern hemisphere.
Volpara share price summary
The past 12 months have been a disappointing run for investors, with the company's shares down almost 11%. When looking at year-to-date, its losses are hovering around 9% over the period.
Based on today's price, Volpara presides a market capitalisation of roughly $329 million and has approximately 251.3 million shares outstanding.
